Matching articles for "bexagliflozin"
In Brief: Empagliflozin (Jardiance) for Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • November 13, 2023; (Issue 1689)
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim/Lilly) is now FDA-approved to reduce the risk of
sustained eGFR decline, end-stage kidney...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim/Lilly) is now FDA-approved to reduce the risk of
sustained eGFR decline, end-stage kidney disease,
cardiovascular death, and hospitalization in adults with
chronic kidney disease (CKD) at risk of progression.
It is also approved to improve glycemic control in
patients ≥10 years old with type 2 diabetes, to reduce
the risk of cardiovascular death and hospitalization
for heart failure (HF) in adults with HF, and to reduce
the risk of cardiovascular death in adults with type 2
diabetes and established cardiovascular disease.
Bexagliflozin (Brenzavvy) — A Fifth SGLT2 Inhibitor for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • August 21, 2023; (Issue 1683)
Bexagliflozin (Brenzavvy – TheracosBio), a sodium-glucose
cotransporter 2 (SGLT2) inhibitor, has been
approved by the FDA to improve glycemic control
in adults with type 2 diabetes. It is the fifth...
Bexagliflozin (Brenzavvy – TheracosBio), a sodium-glucose
cotransporter 2 (SGLT2) inhibitor, has been
approved by the FDA to improve glycemic control
in adults with type 2 diabetes. It is the fifth SGLT2
inhibitor to be approved in the US for this indication
(see Table 4).